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Abstract
Background: Subarachnoid hemorrhage (SAH) patients experience significant headaches that
can last weeks to years. The treatment for these headaches has not been effective in successful
alleviation of pain. Understanding the present standard of care will help guide future medication
modalities for these patients.
Conceptual Framework: The Neuman Systems Model was utilized as a framework in this
study.
Methodology: A retrospective review of the electronic records of patients who experienced a
subarachnoid hemorrhage (SAH) at an academic health system in the southcentral part of the
United States was done to evaluate patient demographics and comorbidities. Variables included
Hunt-Hess (HH) scores, intracranial pressures, aneurysm coiling, and patient-reported pain
scores over the first ten days of hospital admission.
Results: A total of 203 patient electronic medical records were evaluated for this study.
Maximum daily pain score was statistically significant on admission day 5, with a mean for
Hunt-Hess I 5.47, Hunt-Hess II 7.0, and Hunt-Hess III 7.07. Acetaminophen administration (in
milligrams) was 729.59 for HH I, 679.93 for HH II, and 338.82 for HH III on day one of
admission. Admission day 10 was also statistically significant with HH I receiving (in
milligrams) 437.75, HH II receiving 718.42, and HH III receiving 912.76. Morphine equivalent
dosing for day one admissions were HH I 2.69, HH II 5.52, and 0.86 (p=.009).
Discussion: Those patients who presented to the hospital with a SAH with a HH I or HH II had
similar intensity headache, but received more acetaminophen than HH III. On admission day 5,
HH I experienced less headache than HH II or HH III.

Conclusion: Of the patients in the study, all HH classifications presented with similar headache.
Patients with a HH I or HH II received more acetaminophen and opioids than HH III on
admission day I. Those with a HH II and HH III had greater headache on admission day five
than HH I, and received more acetaminophen.
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Treatment of Headache Associated with Subarachnoid Hemorrhage:
A Retrospective Electronic Health Record Review
Introduction
The incidence of aneurysmal subarachnoid hemorrhage (aSAH) is approximately 10 to
15 people per 100,000 (D’Souza, 2015). Because of the acute cerebral injury, this population of
patients experiences significant headaches that can last weeks to years. While the exact
mechanism of headache remains unclear, it is believed to be related to hypertension, meningeal
irritation from the accumulation of blood post-rupture, hydrocephalus, or vasospasm (Swope et
al., 2014). Regardless if organic or mechanical in nature, the treatments for headache include
acetaminophen, acetaminophen/butalbital/caffeine, intravenous magnesium, and opioids,
however none of these have been effective in successful alleviation of pain. While there have
been many articles published about the ineffectiveness of treatment, no new direction for
medication or headache treatments has emerged.
According to Glisc et al., (2012), headaches after SAH occur for more than two weeks
while patients are in the hospital setting. The mean scores of patient-reported headache remains
nearly constant throughout the patients’ treatment course, despite administration of varied
treatment modalities. Glisc et al (2012) further states that this population’s headache persisted in
post-discharge follow-up, in some cases up to nine years. Unfortunately, understanding the exact
cause of headache remains obscure and further complicates effective and reliable treatment.
Additionally, headache was the second leading cause for hospital readmission (Glisc et
al., 2012). Readmission rates are particularly significant for hospital organizations as these rates
impact reimbursement. The Centers for Medicare and Medicaid Services (CMS) and other
insurance institutions have dramatically reduced or eliminated reimbursement for readmissions
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within thirty days for complications related to a previously treated illness. As such, the costs
incurred by the hospitals increase dramatically.
Purpose
The purpose of this study was to determine the maximum daily patient-reported pain
scores for those patients who experienced SAH, and to assess how medications were utilized in
the treatment of headache for those in the study time frame from 2012-2017. Patient selfreported headache pain scores, medication administration for the treatment of pain, intracranial
pressures stratified by Hunt-Hess scoring, and intracerebral interventions were evaluated for
correlation. The data collected were acquired through the electronic health record utilizing the
informatics division of UKCMC, which allowed for consistency of information obtained. The
two electronic data warehouses utilized for this study included the Kentucky Appalachian Stroke
Registry (KApSR) and The Center for Clinical and Translation Science (CCTS).
Theoretical Framework
The Neuman Systems Model was utilized as a conceptual base for this study. Within the
framework for this study, the individual is considered a system whose external environment is
constantly changing. Specific to this model, the “individual” could be a group, community, or a
defined population (Bademli & Duman, 2017). The system’s response to these changes is
dynamic and interacts with their external environment. The model focuses on the individual in
response to stressors within the environment, including all aspects such as psychological,
physiological, spiritual, cultural, and sociocultural (Bademli and Duman, 2017). Understanding
beliefs and structures that are unique to each individualized patient, when possible, aids in the
way to best understand and interpret findings. The Neumann Systems Model is applicable to this
population because the impact of the cerebral injury is specific to each individual and the factors
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that are associated with pain are relative to the individual and their previous experience with
pain.
Literature Review
Evaluation for a subarachnoid hemorrhage (SAH) involves rating headache severity and
level of consciousness, in addition to imaging with computed tomography (CT) and magnetic
resonance imaging (MRI) for the volume of blood in the subarachnoid space. Patient level of
consciousness is evaluated and scored utilizing the Hunt-Hess Classification, with scores ranging
from I-IV (The Joint Commission, 2018). Frequently, patients present to the treating facility
with a headache described as the most severe ever experienced and of significant intensity.
SAH is caused by a rupture of an aneurysm or leakage from an intracerebral vessel,
causing blood to enter the subarachnoid space. Frequently associated with this is cerebral edema
and intraventricular extension as blood moves into the ventricular space. As the blood migrates
into additional areas, this leads to cerebral compression as well as meningeal irritation causing an
exacerbation and prolongation of headache.
Establishing an effective and lasting treatment for headache associated with SAH has
proven to be a challenge. Several medications are theorized to decrease the inflammation
associated with SAH and subsequent headache, including intravenous magnesium,
acetaminophen/butalbital/caffeine, acetaminophen, ibuprofen, ketorolac, morphine, and
dexamethasone (Swope et al., 2014). However, no clinical studies were found that addressed the
cause of headache and associated headache improvement with substantive results for future
treatment. In order to understand any future medical intervention or treatment, establishment of
a historical baseline for patients is of utmost importance. A review of the literature revealed only
limited articles that presented information regarding the degree to which symptomatic headache
9

control is treated in the inpatient hospital setting. Because of variance in patient conditions and
individual patient perception of pain, it is difficult to assess the true cause of the headache and
whether it is mechanical or organic in nature.
Hong et al., (2015) and Glisc et al., (2016) completed retrospective studies that followed
patients for the purpose of evaluating the effectiveness of treatment of headache in patients that
experienced SAH. The researchers determined that treatment of headache was ineffective
throughout the course of hospitalization for these patients. Glisc et al., (2016) found that
headache was the second leading cause for readmission to the hospital within 30 days. Hong et
al., (2015) found that nearly 94% of patients had experienced headache pain improvement at 12
months. Both of these studies underscore the need for improved headache mitigation and
control.
Magalhaes and Rocha-Filho (2013) performed a cohort study of 101 patients from 2009
to 2010 in which patients who presented with aSAH were followed for incidence of headache
and associated medical treatments and interventions. Their study focused on the effects of
embolization and craniotomy. The researchers found that 54% of those who underwent surgical
craniotomies experienced lasting headaches for more than a month. Additionally, 25% of those
who underwent arterial embolization experienced headache at one month follow up.
Endovascular procedures, including angiography with intra-arterial coiling, stenting, or clipping
were overall associated with greater increase and risk for headache (Magalhaes & Rocha-Filho,
2013).
Available literature underscores the need for further research as it relates to SAH, as no
published study has identified a uniformly effective protocol for treating SAH-related headache.
Providers in the medical facility where this study was conducted treat and manage patients in the
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tristate region for SAH. This project focused on historical data, with an emphasis on patients
who were treated for SAH from 2012-2017.
Methods
Design
A retrospective medical record review was used to obtain data to evaluate the headache
scores of patients with aneurysmal and non-aneurysmal subarachnoid hemorrhage who were
admitted to the neurosurgery service line from 2012-2017. KApSR and CCTS were employed
for the compiling of data that met the inclusion criteria for this study. Additional information
collected included intracerebral interventions, specifically aneurysm coiling, and medication
administration for the treatment of headache associated with subarachnoid hemorrhage;
medications included acetaminophen, acetaminophen/butalbital/caffeine, ketorolac, intravenous
magnesium, dexamethasone, and the morphine equivalent for the study time frame.
Sample
A convenience sampling method was used for selection of patients who presented with
SAH in the study time frame. A total of 408 patients were in the data sample from KApSR.
Exclusion criteria included death during admission and a Hunt-Hess classification of IV or V
upon admission to the hospital. Data were evaluated for the first ten days of hospitalization. The
inclusion criteria for this study were as follows: a diagnosis of SAH with a Hunt-Hess
classification I, II or III, admission to the neurosurgery service upon time of hospital admission.
A Hunt-Hess (HH) I classification indicates no neurological impairment, mild headache, and no
nuchal rigidity. A HH II classification indicates full nuchal rigidity, moderate to severe
headache, alert and oriented, and no neurological deficits other than cranial nerve palsy. A HH
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III classification indicates lethargy or mild confusion with mild neurological deficits. Due to the
neurological impairment and depressed level of consciousness and inability to provide feedback
about headache, those with a Hunt-Hess IV or V were excluded from this study.
Setting/Agency Description
The study setting was a Level-1 trauma hospital and Comprehensive Stroke Center (per
The Joint Commission certification), which delivers care to patients from a tristate area who
experience subarachnoid hemorrhage, among multiple other illnesses and disease processes. The
hospital has complete vascular neurology, cerebrovascular surgery, neurointerventional, and
neurocritical care service lines which treat between 35 and 50 SAH per year.
Procedures
Institutional Review Board (IRB) approval was granted through the affiliated university.
KApSR delivered patient demographics (including obesity, hypertension history, tobacco use,
dyslipidemia, age, gender, and race). CCTS provided data that related to daily pain scales,
charted average intracranial pressures on admission days 1-10, and dosage and frequency of
analgesia administered.
Data Analysis
Data were analyzed using SPSS version 24. Descriptive and correlation analyses were
done using patient demographic, classification of HH scoring, patient-reported pain scores,
intracranial pressures, and incidence of aneurysm coiling with p=<.05 considered significant.
Additionally, SAS was employed to complete a post-hoc analysis to determine correlation
between the variable and patient demographic, if any. Any missing data for HH classification
resulted in the exclusion of that participant from the statistical analysis.
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Results
Demographics
A total of 203 patients remained after all exclusion criteria were applied. Significant data
were missing for 31 of the 203 patients, leaving a total of 172 patient medical records for the
study. The mean age of participants was 54.6 years with 62.3% of study subjects being female,
and 89.9% being Caucasian/white. Additionally, 24.3% were obese (defined as a body mass
index > 30 kg/m2), 85.5% had a history of hypertension, 53.4% used tobacco, and 24.3% were
diabetic. (see Table 1 for additional demographic information).
Findings
There were 49 patients with a HH I, 76 patients with a HH II and 47 patients with a HH
III for the study time frame, with data missing for four patients. Patient-reported pain scores
were rated on a scale from 1-10. Maximum daily pain scores were analyzed on admission days
1, 5, and 10, and stratified by Hunt Hess classification. Day 5 of admission was the only time
when a significant difference was noted between Hunt Hess classification, with a mean score of
5.47 (SD 2.94) for Hunt Hess I and 7.0 (2.88) and 7.07 (2.24) for HH II and III, respectively (p =
.023). A post hoc analysis of the data revealed a significant difference between HH I and HH II
and HH I and III, but not between HH II and HH III. There were no significant difference
between the three HH classifications on admission days 1 and 10 (see Table 2).
Cumulative acetaminophen administration was compared for the three HH classifications.
Post hoc analysis revealed a significant difference on admission day 1 (p = .01) with patients
classified as HH I and II receiving more acetaminophen than HH III. On admission day 10,
patients rated as HH II and HH III received significantly more acetaminophen than did patients
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with a HH I classification (p=.02)(see Table 2). The post hoc analysis showed that the morphine
equivalent for admission day 1 was statistically different between the three HH classifications:
HH I mean 2.69 (4.87); HH II mean 5.52 (11.67); and HH III mean 0.86 (2.76). Intravenous
magnesium, ketorolac, and acetaminophen/butalbital/caffeine did not have a statistically
significant impact in the treatment of patient-reported pain scores for the study time frame (see
Table 2).
Aneurysm coiling, a treatment to prevent incidence of additional rupture, was performed
in a total of 97 patients, accounting for roughly 24% of all 408 patients who presented with SAH
during the study timeframe. Statistically significant findings as they relate to patient
demographic and aneurysm coiling can be found in Table 3. As it relates to gender, fifty-seven
percent of those who received an aneurysm coiling were women, compared to only 38% that
were male (p = .014). Fifty-eight percent of the participants in this study who received an
aneurysm coiling used tobacco, compared to 41% of non-tobacco users (p= .02). However, of
those who received an aneurysm coiling, a medical history of diabetes showed an inverse
relationship, with 55.5% not having the disease present, compared to a positive diabetic history
at 34% (p = .01). There was no correlation between intracranial pressures by HH classification
for this study time frame, (see Table 4). The relationship between HH classification and
intracranial pressures from days 1 through 10 can be observed in Graph 1.
Discussion
The purpose of this study was to evaluate the effectiveness of the treatment of headache
associated with SAH. Treatment of headache associated with SAH involves the administration
of multiple medications. In this study, acetaminophen and opioids proved to be more effective in
the treatment of headache than other medications.
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Study findings revealed that women who are Caucasian/white and who used tobacco
were more likely to require an aneurysm coiling than other ethnicities who presented with a SAH
during the study time frame. In line with these results, Lindbohm et al., (2016) found that out of
65,521 individuals who were followed in Finland, women who smoked were three times more
likely to have a SAH than non-smokers. While this current study did not evaluate the
comparison of smokers and non-smokers, the findings do suggest that women have a higher
incidence of SAH and the need for aneurysm coiling than men.
Cumulative acetaminophen dosage for day one was statistically significant in that HH I
and HH II required more medication than HH III. The disparities in acetaminophen
administration could be related to the difference in levels of alertness at the time of admission,
since HH I and HH II patients are more alert and able to report headache pain. The morphine
equivalent dosage findings were the same as acetaminophen on day one of admission, with HH I
and HH II receiving a greater amount of medication than HH III.
On admission day ten there were no significant differences in maximum daily pain
scores, but there was a significant difference in acetaminophen administration, with HH II and
HH III patients receiving higher mean doses of medication than HH I. This finding would
suggest that HH I required less medication to control headache pain than did HH II and HH III.
Related to this finding, Swope et al., (2014) found that pain intensity increased over the first
seven days of admission after a SAH. Their study, which had a slightly different grouping of
HH classifications (HHI - II and HH III-IV), compared daily pain scores and the incidence of
vasospasm which did determine correlation of the two study variables.
Increased intracranial pressure (ICP) is also a prognostic tool in quality outcome for those
patients who experience SAH. This study did not evaluate all five HH classifications for the
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correlation of headache, as the study criteria were dependent upon patient-reported pain scoring
which is only possible with HH I-III. However, in the three HH classifications that were
evaluated, there was no statistically significant differences in HH I-III and ICPs throughout the
ten days of evaluation of this study. This could be due in part to the understanding that those
with HH I-II are not as likely to have a need for ICP monitoring as those who are classified as a
HH III, IV or V. In this study, an average of 17.7% of HH I, 26.7% of HH II, and 88.6% of HH
III had intracranial pressure monitoring for the study time frame. In a study by Wang et al.,
(2104) the researchers found a statistically significant difference in ICP and HH classification,
with a higher HH classification being associated with increased ICP (p< .001).
Limitations
As this was a retrospective review, the researcher was unable to randomize patient
selection. Additionally, information was obtained only from one medical center, limiting the
number of possible participants. The electronic data warehouses utilized for the study only
extracted information that had been charted, regardless of missing or incomplete information.
Data was missing for 31 participants, resulting in a lower overall sample. Further, data were not
collected following discharge to evaluate for headache resolution or continuation or medication
that abated pain associated with SAH. Also, the data compilation only consisted of information
for patients within the first ten days of hospital admission. Frequently, patients who experience
SAH are hospitalized for more than three weeks and continue to experience headache that
requires medication administration.
An additional limitation is that this study did not account for the Fisher score of each
patient. The Fisher grading scale classifies SAH by the degree of blood in the subarachnoid
space and it can help predict the likelihood of cerebral vasospasm (Lindvall et al., 2009). The
16

Fisher scale is used in correlation with HH classification when a patients presents to an admitting
facility with a SAH. Additional limitations are that this study did not account for incidence of
cerebral vasospasm in the study window or for the development of hydrocephalus, both of which
can increase intracranial pressures and associated headache.
Summary and Recommendations
For this study population, women were more likely than men to have a SAH. Cigarette
smokers were more likely to require an aneurysm coiling. Additionally, the data in this study
suggests that patients who present with a subarachnoid hemorrhage for a Hunt Hess I, II and III
classification have headaches that are best treated with an opioid or acetaminophen. It is
suggested that other medications could be administered for the treatment of headache and
evaluated for comparison in a future study.
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Table 1. Patient Demographics

Characteristics
Age
Gender
Female
Male
Ethnicity
White
Black/African American
Others
Obesity
No
Yes
Hypertension
No
Yes
Tobacco
No
Yes
Diabetes
No
Yes
Dyslipidemia
No
Yes

Mean (SD) or n (%)
54.6 (13.1); range = 20-89
124 (62.3%)
75 (37.7%)
177 (89.39%)
12 (7.07%)
6 (3.54%)
146 (75.7%)
47 (24.3%)
28 (14.5%)
165 (85.5%)
90 (46.6%)
103 (53.4%)
146 (75.7%)
43(24.3%)
127 (65.8%)
66 (34.2%)
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Table 2: Pain by Hunt Hess and Medication Administration
Pain Scores and
Medication
Administration

Maximum Daily
Pain Score
Day 1
Day 5
Day 10
Cumulative
Tylenol Dose
Day 1
Day 5
Day 10

Hunt Hess 1
Mean (SD)

Hunt Hess 2
Mean (SD)

Hunt Hess 3
Mean (SD)

p

6.08 (2.1)
5.47 (2.94)a
5.21(3.4)

6.91(2.67)
7.00 (2.88)b
5.97(2.77)

5.48(3.64)
7.07 (2.24)b
5.2(3.29)

.094
.023
.55

729.59 (863.7)a
679.93(677.95)a 338.82(541.95)b
1008.16(1074.31) 1197.37(9.33.24) 1223.94(846.98)
437.75(710.03)a 718.42(955.76)a,b 912.76(728.73)b

.010
.46
.021

Dexamethasone,
number of times
administered

Day 1
Day 5
Day 10

0.06(0.31)
0.61(1.41)
0.06(0.42)

0.18(0.62)
0.68(1.35)
0.21(0.82)

0.02(0.14)
0.42(1.05)
0.21(0.85)

.12
.56
.49

2.69(4.87)a
10.08(22.77)
4.43(11.56)

5.52(11.67)a
13.38(22.38)
8.98(23.55)

0.86(2.76)b
7.75(10.21)
8.47(15.87)

.009
.30
.39

1.5(1.22)
3.5(1.87)
3.0 (2.08)

1.87 (1.45)
3.86 (1.68)
3.0 (1.29)

1 (-)
3 (-)
4 (1.0)

.78
.69
.59

1.0 (-)
1.0 (-)
1.0(-)

1.14(0.37)
1.23(0.43)
1.25(0.5)

1.0 (-)
1.11(0.33)
.29

.60
.52
.29

Morphine
Equivalent

Day1
Day 5
Day 10
Fioricet (number
of
administrations)

Day 1
Day 5
Day 10
Intravenous
Magnesium, 4
grams
(number of
administrations)

Day 1
Day 5
Day 10
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Table 3: Coiling and Comorbidities Correlation
Comorbidities and
Coiling Correlation
Coiling
Yes (n=97)

No (n=96)

Mean (SD) or n (%)

Mean (SD) or n (%)

55.0 (13.6)

54.7 (13.0)

.91

69 (57%)

52 (43%)

.014

28 (38.0%)

44 (61.1%)

Yes

22 (46.8%)

25 (53.2%)

No

75 (51.4%)

71 (48.6%)

Yes

60 (58.3%)

43 (41.7%)

No

37(41.1%)

53 (58.9%)

Yes

16(34%)

31 (66%)

No

81(55.5%)

65 (44.25%)

Yes

28 (42.4%)

38 (57.6%)

No

69 (54.3%)

58 (45.7%)

Yes

82(49.7%)

83 (50.3%)

No

15 (53.6%)

13 (46.4%)

Age

P

Gender
Female
Male
Obesity
.59

Tobacco
.02

Diabetes
.01

Dyslipidemia
0.1

Hypertension

22

.70

Table 4: Intracranial Pressure by Hunt Hess Classification
Intracranial
Pressure (ICP)
by Hunt Hess
Classification
Average Daily
ICP
Day 1
Day 5
Day 10

Hunt Hess 1
Mean (SD)

Hunt Hess 2
Mean (SD)

Hunt Hess 3
Mean (SD)

p

9.7(5.60)
7.85 (4.16)
6.20(2.80)

10.55(4.38)
8.28(4.07)
9.84(4.70)

9.60(3.08)
8.76(4.72)
7.91(4.68)

.65
.81
.12
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Graph 1: Hunt and Hess and ICP Correlation
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